Next Article in Journal
Gemcitabine-Based Regimen for Primary Ovarian Angiosarcoma with MYC Amplification
Previous Article in Journal
Follicular Dendritic Cell Sarcoma of the Stomach: Case Report and Review of the Literature
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 21
Issue 6
10.3747/co.21.2133
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Two Cases of Cutaneous Drug Eruption Associated with Temozolomide Therapy for Glioblastoma

by
E. Deluche
1,*,
S. Leobon
1,
F. Touraine
2 and
P. Clavère
3
1
Department of Medical Oncology, University Hospital, Limoges, France
2
Department of Pneumology, University Hospital, Limoges, France
3
Department of Radiotherapy, University Hospital, Limoges, France
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2014, 21(6), 779-781; https://doi.org/10.3747/co.21.2133
Submission received: 4 September 2014 / Revised: 8 October 2014 / Accepted: 13 November 2014 / Published: 1 December 2014

Abstract

Glioblastoma is the most common form of primary brain cancer. Its treatment involves surgery, radiotherapy, and chemotherapy with temozolomide (TMZ), which is an oral alkylating agent. To the best of our knowledge, few dermatologic side effects of TMZ have been described. We report two cases of cutaneous drug eruption caused by TMZ during and after radiochemotherapy treatment. In the first case, all tests were negative, but the clinical history and the time of onset supported an allergy to TMZ. In the second case, an allergy to TMZ was proved by a positive lymphocyte activation test. In this context, our study is one of a very few trying to determine dermatologic side effects by applicable tests used in routine practice.
Keywords: temozolomide; maculopapular exanthema; glioblastoma temozolomide; maculopapular exanthema; glioblastoma

Share and Cite

MDPI and ACS Style

Deluche, E.; Leobon, S.; Touraine, F.; Clavère, P. Two Cases of Cutaneous Drug Eruption Associated with Temozolomide Therapy for Glioblastoma. Curr. Oncol. 2014, 21, 779-781. https://doi.org/10.3747/co.21.2133

AMA Style

Deluche E, Leobon S, Touraine F, Clavère P. Two Cases of Cutaneous Drug Eruption Associated with Temozolomide Therapy for Glioblastoma. Current Oncology. 2014; 21(6):779-781. https://doi.org/10.3747/co.21.2133

Chicago/Turabian Style

Deluche, E., S. Leobon, F. Touraine, and P. Clavère. 2014. "Two Cases of Cutaneous Drug Eruption Associated with Temozolomide Therapy for Glioblastoma" Current Oncology 21, no. 6: 779-781. https://doi.org/10.3747/co.21.2133

APA Style

Deluche, E., Leobon, S., Touraine, F., & Clavère, P. (2014). Two Cases of Cutaneous Drug Eruption Associated with Temozolomide Therapy for Glioblastoma. Current Oncology, 21(6), 779-781. https://doi.org/10.3747/co.21.2133

Article Metrics

Back to TopTop